Actualités et vidéos - DYNAVAX TECHNOLOGIES - Anglais - Page 2

Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference PR Newswire EMERYVILLE, Calif., Oct. 19, 2023 EMERYVILLE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference on Wednesday, October 25 at 1:00 p.m. ET . The...

Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire EMERYVILLE, Calif., Sept. 6, 2023 EMERYVILLE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 12:00 p.m....

Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance PR Newswire EMERYVILLE, Calif., Aug. 3, 2023 Generated record quarterly HEPLISAV-B ® vaccine net product revenue of $56 million , a 73% year-over-year increase Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million , compared to prior range of $165 - $185 million Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year...

Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023 PR Newswire EMERYVILLE, Calif., July 20, 2023 EMERYVILLE, Calif. , July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023 , after the U.S. financial markets close. Dynavax will host a conference call...

Dynavax to Present at Upcoming Investor Conferences PR Newswire EMERYVILLE, Calif., May 30, 2023 EMERYVILLE, Calif. , May 30, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 43 rd Annual Growth Stock Conference on Tuesday, June 6 at 9:20 a.m. CT...

Dynavax to Present at the JMP Securities Life Sciences Conference PR Newswire EMERYVILLE, Calif., May 8, 2023 EMERYVILLE, Calif. , May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15 , at 1:00 p.m. E.T. The presentation will be webcast and may...

Dynavax Reports First Quarter 2023 Financial Results PR Newswire EMERYVILLE, Calif., May 2, 2023 HEPLISAV-B ® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47% Strengthened balance sheet with cash and investments of $652 million at quarter end and expects positive free cash flow in 2023...

Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023 PR Newswire EMERYVILLE, Calif., April 18, 2023 EMERYVILLE, Calif. , April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2023 financial results on Tuesday, May 2, 2023 , after the U.S. financial markets close. Dynavax will host a conference call and live...

Dynavax to Present at the Cowen 43rd Annual Health Care Conference PR Newswire EMERYVILLE, Calif., March 1, 2023 EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald , Chief Financial Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8 , at 2:10 p.m. E.T....

Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine PR Newswire EMERYVILLE, Calif., Feb. 28, 2023 HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that the United Kingdom's...

Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance PR Newswire EMERYVILLE, Calif., Feb. 23, 2023 2022 total revenue of $723 million , up 64% from $439 million in 2021 HEPLISAV-B ® vaccine net product revenue of $126 million , representing 104% growth compared to 2021 CpG 1018 ® adjuvant vaccine net product revenue of $588 million 2023 HEPLISAV-B net product revenue anticipated to be between $ 165 million and $185 million ,...

Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 PR Newswire EMERYVILLE, Calif., Feb. 9, 2023 EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 , after the U.S. financial markets close....

Dynavax Announces Uplisting to the Nasdaq Global Select Market PR Newswire EMERYVILLE, Calif., Jan. 31, 2023 EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that effective as of market open today, January 31, 2023 , its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue...

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results PR Newswire EMERYVILLE, Calif., Jan. 9, 2023 Preliminary full year 2022 HEPLISAV-B ® vaccine Net Product Revenue of approximately $126 million , representing 104% growth compared to 2021 Preliminary full year CpG 1018 ® adjuvant Net Product Revenue of approximately $588 million Maintained strong financial position with year-end cash and investments of...

Dynavax to Present at Two Upcoming Investor Conferences PR Newswire EMERYVILLE, Calif., Nov. 9, 2022 EMERYVILLE, Calif. , Nov. 9, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, and Kelly MacDonald , Chief Financial Officer, will participate in two upcoming investor conferences: Guggenheim Healthcare Talks | 4th Annual...

Dynavax Reports Third Quarter 2022 Financial Results PR Newswire EMERYVILLE, Calif., Nov. 3, 2022 Q3 2022 total revenue of $167.7 million , up 55% from $108.3 million for Q3 2021 HEPLISAV-B ® vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 CpG 1018 ® adjuvant net product revenue of $126.3 million , up 50% from $84.3 million for Q3 2021 Reiterates guidance for full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million On track...

Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022 PR Newswire EMERYVILLE, Calif., Oct. 20, 2022 EMERYVILLE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter financial results on Thursday, November 3, 2022 , after the U.S. financial markets close. Dynavax will host a conference call and live...

Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine PR Newswire EMERYVILLE, Calif., Sept. 12, 2022 EMERYVILLE, Calif. , Sept. 12, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, in collaboration with the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear...

Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire EMERYVILLE, Calif., Sept. 8, 2022 EMERYVILLE, Calif. , Sept. 8, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference,...

Thinking about buying stock in AN2 Therapeutics, AMTD IDEA Group, Dynavax Technologies, Yelp, or Honest Company? PR Newswire NEW YORK, Aug. 5, 2022 NEW YORK , Aug. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANTX, AMTD, DVAX, YELP, and HNST. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ANTX:...